ISAL 2019 | MRD detection for AML in China & MFC to detect CEPBA mutations
Hong-Hu Zhu
• 25 Feb 2019
Measurable residual disease (MRD) monitoring can be performed using a number of methods, including multiparametric flow cytometry (MFC) and PCR. We spoke to Hong-Hu Zhu, MD, PhD, of The First Affiliated Hospital, Zhejiang University, Hangzhou, China, about the use of MRD measurement in China, as well as his recent research intro the use of MFC to detect MRD in acute myeloid leukemia (AML) with CEBPA mutations. This interview took place at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.
